FRANKLIN, Mass., Jan. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the OneMedForum 2011 annual healthcare conference held January 10-13th in San Francisco, CA.
Dr. Mooney will make a corporate presentation to prospective corporate partners and investors on Tuesday, January 11 at 4:15 PM PST. The Company's presentation will be delivered in the Renaissance Room at The Sir Francis Drake Hotel, Union Square, San Francisco, CA.
About OneMedForum 2011The fourth annual OneMedForum event continues to be a vital connecting point for healthcare/life science-focused emerging companies, business development executives and investors. The three-day event will include industry-focused panel sessions, numerous networking opportunities, and more than 125 presentations by some of the most promising emerging medical device, biotech and health information companies. OneMedForum San Francisco 2011, runs concurrently with the J.P Morgan conference that provides efficient access to the companies that shape the future of the rapidly changing healthcare landscape.
About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.
Media: Richard SternChairman and Chief Executive Officer
Stern & Co.(508) 530-0329
|SOURCE Echo Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved